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In the last years, physiological aging became a general concept that includes all the changes that occur in
organism with old age. It is obvious now, that in developing and developed countries, new health problems
concerning older population appear. One of these major concerns is probably dementia. Sooner or later, all forms
of dementia lead to learning deficit, memory loss, low attention span, impairment of speech and poor problem
solving skills. Normal ageing is a physiological process that also involves a lot of neurological disorders with the
same type of symptoms and effects that many researchers are trying to minimize in demented patients. In this
review we try to highlight some of the newest aspects of therapeutic strategies that can improve natural
neuroregeneration.
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With longer life span, especially in developing and devel-
oped countries, new health problems concerning specific
needs of older populations arise. One of the major
health concerns in this aspect is dementia.
Dementia is a clinical term used to characterize a
number of diseases with neuropsychiatric symptoms,
that are not explained by delirium or major psychiatric
disorder and interfere with one's ability to function with
usual activities [1] but dementia as a biological aspect of
the clinical term has many different causes.
All changes that occur in all organs and systems asso-
ciated with old age is now generally accepted as physio-
logical ageing. This concept is characterized by the
declining ability to respond to different types of stress,
homeostatic imbalance and diseases.
Brain ageing is associated with structures and func-
tions decline both is neurons and glia. This is generally
referred as neurodegeneration. It is a normal process
that can lead to reductions in communication and in* Correspondence: adrian.balseanu@webmail.umfcv.ro
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reproduction in any medium, provided the ormemory function [1,2] but also to poor recovery after
stroke [3].
Neurodegeneration is a progressive process that occurs
because of a decline in the total number of neurons;
generally, this process is due to apoptosis and is associ-
ated with a loss of neuronal structure and function [4].
Ageing is considered the most important risk factor for
brain degeneration and age-related cognitive disorders [5].
Elucidating the cellular and molecular basis of neuro-
degeneration and neuroregeneration and how they are
involved in the aging brain could reveal new therapeutic
approaches to dementia in the elderly.
Overall, we aimed at summarizing up to-date findings
described and evaluated by a number of different authors
and by discussing contradictory results of different re-
searcher groups we want to highlight the complexity of
the presented problem.Review
Neuroregeneration and aging
Physiological ageing is now generally accepted as a con-
cept that includes all the changes that occur in all organs
and systems associated with old age, characterized by
the declining ability to respond to different types of
stress, homeostatic imbalance and diseases.
The phenomena involved in brain ageing are associ-
ated with a decline of the neuronal and glial structuresLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nication and in memory function [1,2] and also to poor
recovery after stroke [3].
Neurodegeneration is a progressive process that occurs
because of a decline in the total number of neurons;
generally, this process is due to apoptosis and is associated
with a loss of neuronal structure and function [4]. Ageing
is considered the most important risk factor for brain
degeneration and age-related cognitive disorders [5].
An increasing susceptibility to poor recovery from
brain injury has been observed in the elderly. Regener-
ation of neuronal tissue makes no exception however
the pathways for the cellular processes that characterize
these phenomena have yet to be found.
From a morphological and functional perspective neuro-
regeneration implies a restorative process involving central
nervous system tissue and neural network architecture.
From a clinical point of view, brain-repairing pathways
require the removal of the aetiological factors that caused
the damage after the inflammatory response, to impede
the degeneration of cells and to restore the neural cells or
their network [6].
The concept of neuregeneration can be also defined as
the superposition of three distinctive processes including
neurogenesis, neuroplasticity and neurorestoration [7]. It
is known that the mammalian brain is one of the organs
with a very low level of cell replacement. Still, neuro-
genesis is now generally accepted and neural stem cells
have been discovered in different specific brain regions,
including hippocampus [8].
However, older organisms, including humans, have re-
ported a decline in the rate of neurogenesis. Hippocam-
pal neurogenesis seems to persist also in adult age. With
ageing, the proliferation and differentiation of neural
progenitors are significantly decreased with a higher
number of newborn death neurons.
One possible explanation for this decline can be that
the neural stem cells are entering in a quiescent state,
supported by the hypothesis that aged neural stem cells
are intrinsically different from the younger one. Another
possibility can be that the expression of some transcrip-
tion factors (Er81 and Dlx2) associated with neural de-
velopment are reduced in the elderly [9].
Another effect can be the reduction in telomerase ac-
tivity. A study on adult mice deficient in telomerase ac-
tivity, reported poor neurogenesis in hippocampal areas,
associated with a lower number of proliferation (Ki67+)
or immature (Dcx+) cells [10].
Nevertheless, extrinsic factors from the local environ-
ment (neurogenic niche) can regulate neurogenesis. In
old age, lower levels for different growth factors that can
facilitate neurogenesis (fibroblast growth factor-2, insulin
growth factor-1 or vascular endothelial growth factor)
were registered in the hippocampal area [11]. A declinein angiogenesis in cerebrovascular area observed in aged
mammals [12] can also modify the neurogenic niche by
decreasing the source of growth factors.Ageing and dementia
As populations get older due to a longer life span, espe-
cially in developing and developed countries, new health
problems concerning specific needs of older populations
arise. One of the major health concerns in this aspect is
dementia.
Dementia has many different causes. Dementia is seen
as a clinical term used to characterize a number of dis-
eases such as Alzheimer's disease dementia, Lewy bodies
dementia, vascular dementia, behavior variant fronto-
temporal dementia, primary progressive aphasia or any
cognitive/behavioral changes with neuropsychiatric symp-
toms, that are not explained by delirium or major psychi-
atric disorder and interfere with one's ability to function
with usual activities [1,2].
At the moment it is estimated that 35.6 million people
worldwide are diagnosed with dementia. It is predicted
that in approximately 20 years this number will double
and triple in the next 40 years [13].
Based on all the information the scientific community
has gathered, the diagnostic criteria for dementia has be-
came more accurate [1,12]. Treatment and management
of dementia are generated by research based on results
from studies. Test subjects are patients with early stages
of dementia Figure 1 [14]. As the population gets older,
new criteria for diagnosing old elderly persons (>75
years old) are needed because the border between non
pathological aged brain and dementia brain is becoming
more unclear with age [15].
As one gets older, multiple risk factors varying from
childhood IQ [16], obesity in middle age [17], smoking,
hypertension, high cholesterol and diabetes at midlife
[18,19] to stroke and atrophy in old age [15] contribute
to dementia in the elderly. Scientific progress has found
that a small number of highly conserved genes can have
a positive effect on the length of a life span. These genes
act through a number of metabolic processes like the
“reactive oxygen species” (ROS) representing one of the
most incriminated and poorly understood contributors
to brain ageing [20]. Acquiring defense from dietary an-
tioxidants can protect against ROS induced damage [16].
It is believed that the brain has a neuronal reserve to
compensate for any loss at old age. However the cause
of dementia is a more rapid neuronal death as found in
alcohol abuse, unhealthy eating, smoking, stroke. Re-
gardless of the risk factors, dementia is still a con-
sequence of neuronal populations loss that cannot be
compensated. It is unclear as to why there is such large
individual variability in our population.
Figure 1 Representation of age distribution for patients suffering from dementia. Broken line shows patients that were included in clinical
research of diagnostic methods and therapeutic trials. Solid line shows demented patients age distribution from the general population of the
Netherlands [14].
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as people get older, it is harder to distinguish between a
normal aged brain and a dementia affected brain [15]. A
constant increase in neuritic plaques and tangles in the
hippocampus and neocortex of non-dementia diagnosis
persons are parallel with constant decrees in the same
features of a dementia brain. The only objective and
quantifiable diagnostic criteria still remaining valid in
both old elderly persons (> 75 years old) as of young
elderly persons (< 75 years old) is cerebral atrophy [15].
Furthermore, neuropathological examination can some-
times detect individuals with microscopic features typ-
ical of late-onset Alzheimer’s but no clinical history of
dementia was described before death. Other times,
individuals diagnosed with late stage dementia during
their life can show only mild pathological features of
Alzheimer’s disease [16].
It is still not clear if cerebrovascular disease induces
dementia or if both have the same risk factors and thus
are indirectly linked. Despite all that, huge evidence
associating stroke to dementia is simply undisputed,
making it just more probable that stroke itself is a risk
factor for dementia and not just a more acute conse-
quence [21]. Studies on cerebrovascular system in the
elderly populations have found that the blood brain bar-
rier permeability increases with normal age, and can lead
to the initiation or worsening of cerebral microvascular
disease [22] or dementia.
An overlap can be found between vascular dementia
and Alzheimer dementia. As previously noted [23], spon-
taneous cerebral emboli were detected in 43% of AD
patients and 45% in VaD cases. These results were associ-
ated with a cognitive and functional decline within 2 years
from the measurements. It was also found during this
study that patients had an increase in psychiatric symp-
toms [24]. Most of these studies suggest that AD patientshave a lower mean flow velocity than normal elderly
patients [25,26]. However some groups did not find any
difference between AD patients and normal old persons
[27,28].
In the last 65 years, epidemiological studies have
shown a double increase for the risk of being diagnosed
with dementia [21]. The same studies determine that
there is a risk of post-stroke dementia; this is dependent
on the existence of pre-stroke cognitive impairment.
Interestingly, stroke survivors who did not develope
dementia symptoms at the age of 85 year have no in-
creased risk of dementia compared to stroke free older
persons. Neuropathological findings have shown that the
burden and location of cerebral infarcts are associated
with a cognitive decline [29]. However no evidence was
found that stroke prevention treatments, especially anti-
hypertensive tretments, have any effect on dementia in-
cidence [30], although cohort studies found that statin
treated patients seems to have a decrease risk of vascular
dementia [31].
Understanding individual differences in age related
cognitive decline and dementia is more difficult than we
like to admit. The best available neuropathological evi-
dence of the hypothetical difference between ‘normal’
ageing and dementia are scarce [16], suggesting there
are no boundaries between them [15].
As molecular biology gets increasingly involved in the
description of dementia, we hope that the border be-
tween different subtypes of dementia will slowly become
clearer. By doing this we hope that we can find some
means to postpone or even prevent dementia altogether.
Treatment
“Early onset dementia”, a sub-type of dementia that oc-
curs before the age of 65, or “late onset dementia”, more
common among the geriatric population, both lead the
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Therefore, many studies seek other ways of renewing
“the natural cargo” of the brains neurons, in order to
remove various behavioral and psychological symptoms
of dementia.
A promising approach regarding central nervous sys-
tem degenerative diseases is a recombinant DNA vaccine
composed of multiple specific inhibitory domains of
NOIs (neurite outgrowth inhibitors). The mechanism of
the treatment is an immunological one, inducing effect-
ive antibodies against the specific domains in the sera of
mice treated with a DNA primed-vaccinia virus boost
regimen. Three good responses were observed: little
formation of soluble Aβ oligomer and amyloid plaques
in the co-transgenic mice brain (incriminated in the
physiopathology of Alzheimer’s disease), attenuated neu-
ronal degeneration and protection against behavioral
deficits [32]. The modulation of mRNA expression regard-
ing NOIs was also obtained using generated channel-
rhodopsin-mutant protein expressing microglia, a sodium
channel activated by light irradiation. By increasing the
intracellular level of the ion, this technique can control
microglial activation and thus cause repair/regeneration of
neural and oligodendrocytic damage [33].
Stem cells might be a real alternative to brain regener-
ation in neurodegenerative disorders such as dementia,
because they are capable of being integrated into a de-
generative environment (the differentiation potential
towards site appropriate phenotypes) and releasing neuro-
trophic cytokines. Quantification of the cytokines that
may sustain endogenous neurogenesis and/or activate
neuroprotective pathways (for nestin and connexin 43)
revealed a neurogenic/angiogenic predisposition of naive
human chorial villi and amniotic fluid derived cells. These
cells also release significant amounts of brain-derived
neurotrophic factors, as well as vascular endothelial
growth factor [34].
Some ongoing clinical research trials, predict a chance
for therapy using only neurotrophic factors: the neuro-
trophin nerve growth factor (NGF), glial cell-derived
neurotrophic factor (GDNF) and brain-derived neuro-
trophic factor (BDNF). Already, some degree of success
has been obtained with GDNF and NGF regarding the
survival, existence and regeneration of specific neuronal
populations in the adult brain suffering from Parkinson's
or Alzheimer's disease [35,36].
Some natural substances were also used to help neur-
onal self-healing. Among them, Cerebrolysin represents
a therapeutic strategy for neurological disorders like
dementia, stroke and traumatic brain injury. It is a pep-
tide preparation mimicking the action of neurotrophic
factors. Studies in vitro (biochemical and cell cultures)
or in vivo (on animal models) show the multiple benefits
of the natural drug (a pig brain extract). The drugsenhances neurogenesis in the dentate gyrus (the basis
for neuronal replacement therapy in neurodegenerative
diseases), but also in the subventricular zone (SVZ) sus-
taining the brain's self-repair. It also promotes neural
progenitor cell migration, increases synaptic density re-
building neuronal cytoarchitecture, induces restorative
processes, decreases the infarct volume and edema for-
mation and promotes functional recovery [37].
One study on neuronal precursor cells - Nestin+ and
GFAP+ (glial fibrillary acidic protein) - isolated and cul-
tured from adult rat SVZ, obtained good results using a
pre-treatment of Quercetin in a dose–response manner.
The natural flavonoid could be protective of neuronal
precursors of adult brain by neutralizing the oxidative
stress (reduces peroxynitrite formation, protein nitration
and M2 isoform of pyruvate kinase depletion) [38]. An-
other flavonoid, isoquercitrin also promotes neuronal
differentiation through multiple Rho GTPase mediated
mechanisms. One possible mechanism is the inactivation
of RhoA/Rho kinase: isoquercitrin reduces 47% of the
RhoA activity and induces neurite growth (at concentra-
tions ≥ 40 μM). Another mechanism is the affection of
RhoA localization that underwent translocation to the
cytoplasm [39].
Hormonal substances like the neurosteroid allopreg-
nanolone (APα, 3α-hydroxy-5α-pregnan-20-one), a me-
tabolite of progesterone that is normally generated in the
nervous system, were also used for research with good
results. In a triple transgenic mouse model of AD it
promoted neurogenesis, improved the cognitive function
and reversed the neurogenic deficits in the hippocampal
dentate gyrus and the cerebral subventricular zone
[40,41].
Melatonin, the pineal product, has good antioxidant
properties and has been shown to be useful in stopping
neurodegenerative phenomena seen in experimental mo-
dels of Alzheimer's disease, Parkinsonism and ischemic
stroke. In clinical trials using treatments with mela-
tonin has been effective in slowing the progression of
Alzheimer's disease, but not of Parkinson's disease.
Melatonin has multiple ways of preserving mitochon-
drial homeostasis. It reduces free radical generation by
enhancing mitochondrial glutathione levels and it safe-
guards proton potential and ATP synthesis by stimulating
complex I and IV activities [42].
Conclusion
The available evidence indicates that one of the major
health problems concerning the older population in de-
veloped countries will be dementia. It is a concern in the
healthcare community that therapeutic strategies avail-
able do not address the cause of the pathology but are
more focused on treating symptoms and providing sup-
port to patients.
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found in elderly populations, further compromising the
recovery of an injured brain.
Elucidating the cellular and molecular basis for in-
volved in neurodegeneration and neuroregeneration in
the aging brain could reveal new therapeutic approaches
to dementia in the elderly.
Development of novel and effective therapies to sustain
the brain's self-repair, using either molecular modulation
of mRNA expression, stem cell therapy, neurotrophic
factors or even drugs derived from natural sources will
hopefully lead to an improved management of dementia
in older population.
Multiple strategies should be targeted to prevent the
development and the progression of the disease. Further
investigation to update these strategies are required for
an efficient therapeutic response in dementia.
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